Aquatic Capital Management LLC Acquires 21,291 Shares of Infosys Limited (NYSE:INFY)

Aquatic Capital Management LLC boosted its position in shares of Infosys Limited (NYSE:INFY - Free Report) by 4.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 523,091 shares of the technology company's stock after buying an additional 21,291 shares during the quarter. Aquatic Capital Management LLC's holdings in Infosys were worth $11,466,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Barclays PLC lifted its position in shares of Infosys by 11.8% during the 3rd quarter. Barclays PLC now owns 2,523,605 shares of the technology company's stock valued at $56,200,000 after acquiring an additional 266,902 shares during the last quarter. Tudor Financial Inc. purchased a new stake in shares of Infosys during the third quarter valued at $496,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Infosys in the 3rd quarter valued at $57,000. Tidal Investments LLC increased its stake in Infosys by 31.6% in the 3rd quarter. Tidal Investments LLC now owns 42,315 shares of the technology company's stock worth $942,000 after purchasing an additional 10,149 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in Infosys by 2.9% during the 3rd quarter. Franklin Resources Inc. now owns 11,272,051 shares of the technology company's stock worth $263,315,000 after buying an additional 322,648 shares during the period. 16.20% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on INFY. CLSA upgraded shares of Infosys from a "hold" rating to an "outperform" rating in a report on Friday, March 7th. Stifel Nicolaus cut their target price on shares of Infosys from $18.00 to $17.00 and set a "hold" rating on the stock in a research note on Monday, April 21st. StockNews.com cut Infosys from a "buy" rating to a "hold" rating in a research report on Wednesday, April 23rd. BMO Capital Markets lowered their price target on Infosys from $25.00 to $18.00 and set a "market perform" rating on the stock in a report on Monday, April 21st. Finally, Investec upgraded Infosys from a "sell" rating to a "buy" rating in a research report on Friday, April 18th. Seven analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $17.48.

Infosys Trading Up 0.2 %

INFY stock traded up $0.04 during trading on Wednesday, hitting $17.61. 7,083,183 shares of the stock traded hands, compared to its average volume of 11,958,400. The stock has a market cap of $72.94 billion, a price-to-earnings ratio of 22.29, a P/E/G ratio of 3.50 and a beta of 0.97. Infosys Limited has a one year low of $15.82 and a one year high of $23.63. The company has a 50 day simple moving average of $18.25 and a 200 day simple moving average of $20.82.

Infosys (NYSE:INFY - Get Free Report) last posted its quarterly earnings data on Thursday, April 17th. The technology company reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.01. The company had revenue of $4.79 billion for the quarter, compared to analyst estimates of $420.69 billion. Infosys had a return on equity of 31.60% and a net margin of 17.28%. During the same quarter in the previous year, the firm earned $0.23 earnings per share. As a group, analysts predict that Infosys Limited will post 0.74 earnings per share for the current fiscal year.

Infosys Profile

Infosys Ltd. is a digital services and consulting company, which engages in the provision of end-to-end business solutions. It operates through the following segments: Financial Services, Retail, Communication, Energy, Utilities, Resources, and Services, Manufacturing, Hi-Tech, Life Sciences, and All Other.